Transaction #12857 · Form 4 · 0002043558-25-000003
Verrica Pharmaceuticals Inc. · Purchase · Series C Warrant (right to buy)
Verrica Pharmaceuticals Inc. · Transacted November 25, 2025 · Filed November 25, 2025
What does this filing report?
An SEC Form 4 filing for Verrica Pharmaceuticals Inc. records a purchase involving Series C Warrant (right to buy) on November 25, 2025. The reported quantity was 23,577. The filing date is November 25, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Verrica Pharmaceuticals Inc.
- Company CIK
- 0001660334
- Security type
- Derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 23,577
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 23,577
- Ownership description
- Not reported
- SEC acceptance time
- Nov 25, 2025, 7:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Rieger Jayson ↗
CEO and President · Director
CIK 0002043558
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 23,577
- Conversion / exercise price
- 6.315
- Exercise date
- Not reported
- Expiration date
- November 25, 2030
Filing footnotes & remarks
- F1
- Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
- F2
- These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F3
- Immediately exercisable.
- F4
- The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.